MLT-231
- CAS No.
- 2682102-10-7
- Chemical Name:
- MLT-231
- Synonyms
- MLT-231
- CBNumber:
- CB59628152
- Molecular Formula:
- C19H19ClF3N7O2
- Molecular Weight:
- 469.85
- MDL Number:
- MOL File:
- 2682102-10-7.mol
- MSDS File:
- SDS
MLT-231 price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0142774 | MLT-231 99.55% | 2682102-10-7 | 5mg | $628 | 2026-06-04 | Buy |
| ChemScene | CS-0142774 | MLT-231 99.55% | 2682102-10-7 | 10mg | $1029 | 2026-06-04 | Buy |
| ChemScene | CS-0142774 | MLT-231 99.55% | 2682102-10-7 | 25mg | $2058 | 2026-06-04 | Buy |
| ChemScene | CS-0142774 | MLT-231 99.55% | 2682102-10-7 | 50mg | $3250 | 2026-06-04 | Buy |
| ChemScene | CS-0142774 | MLT-231 99.55% | 2682102-10-7 | 100mg | $5200 | 2026-06-04 | Buy |
MLT-231 Chemical Properties, Uses, Production
Uses
MLT-231 is a potent, highly selective allosteric MALT1 Inhibitor with an IC50 of 9 nM. MLT-231 specifically prevents endogenous BCL10 cleavage with IC50 of 160 nM. MLT-231 shows antitumor activity in an ABC-DLBCL type xenograft model in mouse[1].
in vivo
MLT-231 (10-100 mg/kg; p.o.; bid schedule for 2 weeks) displays in vivo efficacy in the ABC-DLBCL xenograft model[1].
MLT-231 (1 mg/kg; i.v.; BALB/c mice) treatment shows the CL, t1/2, and Vss are 11 mL/min/kg, 1.9 hours, and 1.5 L/kg, respectively[1].
MLT-231 (1 mg/kg; i.v.; Sprague-Dawley rats) treatment shows the CL, t1/2, and Vss are 41 mL/min/kg, 3.2 hours, and 9.4 L/kg, respectively[1].
MLT-231 (3 mg/kg; p.o.; BALB/c mice) treatment shows the AUC0-24, Cmax and F are 3096 nM/h, 549 nM, and 99%, respectively[1].
MLT-231 (3 mg/kg; p.o.; Sprague-Dawley rats) treatment shows the AUC0-24, Cmax and F are 547 nM/h, 46 nM, and 61%, respectively.
| Animal Model: | Scid-beige mice (OCI-Ly10 ABC-DLBCL type xenograft model)[1] |
| Dosage: | 10, 30, and 100 mg/kg |
| Administration: | P.o.; bid schedule for 2 weeks |
| Result: | Led to tumor stasis, while being well tolerated. |
References
[1] Pissot Soldermann C, et al. Discovery of Potent, Highly Selective, and In Vivo Efficacious, Allosteric MALT1 Inhibitors by Iterative Scaffold Morphing [published online ahead of print, 2020 Nov 30]. J Med Chem. 2020;10.1021/acs.jmedchem.0c01245. DOI:10.1021/acs.jmedchem.0c01245
MLT-231 Preparation Products And Raw materials
Raw materials
Preparation Products
MLT-231 Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| ShangHai Caerulum Pharma Discovery Co., Ltd. | 18149758185 18149758185 | sales-cpd@caerulumpharma.com | China | 3493 | 58 |
| Shanghai Beckham Medical Technology Co., Ltd | 13816613772 | huahero21@sina.com | China | 2994 | 55 |
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89664 | 60 |
